Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?

Dionisio D, Cao Y, Hongzhou L, Kraisintu K, Messeri D.

Curr HIV Res. 2006 Jan;4(1):3-20. Review.

PMID:
16454707
2.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
3.

Production of antiretroviral drugs in middle- and low-income countries.

Pinheiro Edos S, Brüning K, Macedo MF, Siani AC.

Antivir Ther. 2014;19 Suppl 3:49-55. doi: 10.3851/IMP2900. Epub 2014 Oct 13. Review.

PMID:
25310755
4.

Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.

Orsi F, d'almeida C.

Curr Opin HIV AIDS. 2010 May;5(3):237-41. doi: 10.1097/COH.0b013e32833860ba. Review.

PMID:
20539080
5.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
6.

Differential pricing for pharmaceuticals: reconciling access, R&D and patents.

Danzon PM, Towse A.

Int J Health Care Finance Econ. 2003 Sep;3(3):183-205. Review.

PMID:
14625999
7.

Priority strategies for sustainable fight against HIV/AIDS in low-income countries.

Dionisio D, Esperti F, Messeri D, Vivarelli A.

Curr HIV Res. 2004 Oct;2(4):377-93. Review.

PMID:
15544458
8.

Intellectual property rights, market competition and access to affordable antiretrovirals.

Pascual F.

Antivir Ther. 2014;19 Suppl 3:57-67. doi: 10.3851/IMP2901. Epub 2014 Oct 13. Review.

PMID:
25309984
9.

TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.

Orsi F, D'Almeida C, Hasenclever L, Camara M, Tigre P, Coriat B.

AIDS. 2007 Oct 1;21(15):1997-2003. Review. No abstract available.

PMID:
17885289
10.

Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.

Ford N, Wilson D, Costa Chaves G, Lotrowska M, Kijtiwatchakul K.

AIDS. 2007 Jul;21 Suppl 4:S21-9. Review.

PMID:
17620749
11.

Conflicts of interest in research involving human beings.

Greco D, Diniz NM.

J Int Bioethique. 2008 Mar-Jun;19(1-2):143-54, 202-3. Review.

PMID:
18664007
12.
13.

The World Health Organization and the Pharmaceutical Industry. Common areas of interest and differing views.

Hardwicke CJ.

Adverse Drug React Toxicol Rev. 2002;21(1-2):51-99. Review.

PMID:
12140907
14.

[Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].

Chaves GC, Oliveira MA, Hasenclever L, de Melo LM.

Cad Saude Publica. 2007 Feb;23(2):257-67. Review. Portuguese.

15.

Global trade and health: key linkages and future challenges.

Bettcher DW, Yach D, Guindon GE.

Bull World Health Organ. 2000;78(4):521-34. Review.

16.

Generic and branded drugs for the treatment of people living with HIV/AIDS.

Bartlett JA, Muro EP.

J Int Assoc Physicians AIDS Care (Chic). 2007 Mar;6(1):15-23. Review.

PMID:
17329500
17.
19.

The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.

Jadhav S, Datla M, Kreeftenberg H, Hendriks J.

Vaccine. 2008 Mar 20;26(13):1611-5. doi: 10.1016/j.vaccine.2008.01.034. Epub 2008 Feb 6. Review.

PMID:
18294742
20.

Access to antiretroviral treatment in Latin American countries and the Caribbean.

Chequer P, Cuchí P, Mazin R, García Calleja JM.

AIDS. 2002 Dec;16 Suppl 3:S50-7. Review.

PMID:
12685925

Supplemental Content

Support Center